Vera Therapeutics Completes Patient Enrollment in Phase 2b ORIGIN Clinical Trial of Atacicept for the Treatment of IgA NephropathyGlobeNewsWire • 07/06/22
Vera Therapeutics Reports Positive Interim Phase 2 Data Showing MAU868 Has Significant BK Antiviral Activity in Kidney Transplant PatientsGlobeNewsWire • 06/04/22
Vera Therapeutics Announces New Atacicept Phase 2 Clinical Data in Two Oral Presentations at the 59th European Renal Association CongressGlobeNewsWire • 05/20/22
Vera Therapeutics Provides Business Update and Reports First Quarter 2022 Financial ResultsGlobeNewsWire • 05/16/22
Vera Therapeutics Announces Two Oral Presentations at the 59th European Renal Association – European Dialysis and Transplant Association Congress Featuring New Clinical Data on Atacicept in IgA Nephropathy and in Systemic Lupus ErythematosusGlobeNewsWire • 05/03/22
Vera Therapeutics Selected to Present Interim Phase 2 Data for MAU868 to Treat BK Virus in Kidney Transplant Patients as Oral Late-Breaker at the American Transplant Congress 2022GlobeNewsWire • 05/02/22
Vera Therapeutics Reports Fourth Quarter and Full Year 2021 Financial ResultsGlobeNewsWire • 03/24/22
Vera Therapeutics to Participate in the 42nd Annual Cowen Health Care ConferenceGlobeNewsWire • 03/01/22
Vera Therapeutics Announces Closing of Upsized Public Offering of Class A Common Stock and Full Exercise of Underwriters' Option to Purchase Additional SharesGlobeNewsWire • 02/14/22
Vera Therapeutics Announces Phase 3 Clinical Trial for Atacicept in Lupus NephritisGlobeNewsWire • 01/18/22
Vera Therapeutics to Present at the 40th Annual J.P. Morgan Healthcare ConferenceGlobeNewsWire • 01/04/22
Vera Therapeutics Announces Acquisition of Monoclonal Antibody From Pfizer to Treat BK Virus in Transplant PatientsGlobeNewsWire • 12/17/21
Vera Therapeutics Announces Appointment of Kimball Hall to Board of DirectorsGlobeNewsWire • 12/14/21
Vera Therapeutics to Present at Upcoming Investment Conferences in November 2021GlobeNewsWire • 11/10/21
Vera Therapeutics Reports Third Quarter 2021 Financial Results and Provides Corporate UpdateGlobeNewsWire • 11/10/21
Vera Therapeutics Presents Phase 2a Data Showing Atacicept Reduces Serum Gd-IgA1 in Patients with IgA Nephropathy at the American Society of Nephrology Kidney Week 2021GlobeNewsWire • 11/04/21
Vera Therapeutics to Present Phase 2a Data on Atacicept in IgA Nephropathy at the American Society of Nephrology Kidney Week 2021 Annual MeetingGlobeNewsWire • 10/13/21